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ABSTRACT  
Several studies suggest that gender may affect cystic fibrosis (CF) disease severity, with 
women with CF being more severely affected. In this context it has been suggested that sex 
hormones may influence the CF phenotype. A large proportion of women with CF regularly 
use oral contraceptives (OC), but the effect of their use on disease severity is unclear.  Here, 
we retrospectively assessed the effects of OC on clinical outcomes in women with CF.  
Data from 681 women were available of whom 42% had taken OC for varying periods of 
time. We first performed an inter-patient analysis comparing annual change  in %predicted 
FEV1, body mass index (BMI) and total days of intravenous (IV) antibiotic use over a five 
year study period in 57 women exposed to and 57 women not exposed to OC. There were no 
differences between the two groups. We next performed an intra-patient analysis of the same 
outcomes over a three year period of OC exposure and a three year period of no OC exposure 
in the same patient (n=23-27), but again did not detect any differences in any of the clinical 
outcomes.  
Our data suggests that the use of OC does not affect CF disease severity. 
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INTRODUCTION 
Pulmonary disease progression in cystic fibrosis (CF) is heterogeneous. This may in part be 
related to the different classes of CFTR mutations having different effects on protein 
function.[1]  However, even patients with the same mutation frequently differ with respect to 
pulmonary disease progression. It has been shown that socio-economic status, adherence and 
access to treatment as well as modifier genes contribute to progression of CF lung disease.[2] 
In addition it has been suggested that gender may have an effect on CF mortality with women 
dying earlier than males;[3-5] and on morbidity since  it has been suggested that women with 
CF acquire chronic Pseudomonas aeruginosa infection earlier and that this is linked to an 
accelerated decline of pulmonary function.[6,7] Verma et al suggest that the gender-gap in 
childhood and adolescence closes when both sexes receive standardised aggressive treatments 
in a single centre.[8]  
It has been suggested that sex hormones may directly influence the CF phenotype by altering 
ion transport in epithelial cells. These effects have been investigated in vivo by Sweezey et al 
who showed that the amiloride-insensitive component of nasal potential difference (NPD) 
varies during the menstrual cycle in CF females.[9] During the luteal phase (high 
progesterone) amiloride-insensitive NPD was significantly higher than during the follicular 
phase (low progesterone). This suggests that elevated progesterone during the luteal phase 
may alter ion transport across the respiratory epithelium which may alter the height of the 
periciliary liquid and, therefore, mucociliary clearance.  
In vitro studies assessing the effects of sex hormones on ion transport have produced 
conflicting results with some studies reporting inhibition of chloride transport [10,11] and 
others showing increased CFTR transcription after sex hormone exposure. [12-14] Fanelli et 
al observed an increase in processing of misfolded CFTR leading to improved ion transport 
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in a CF human bronchiolar epithelial cell line and proposed that oestrogens rescue misfolded 
ΔF508 CFTR from proteosomal degradation, thereby increasing the amount of functional 
CFTR at the cell membrane.[15] In addition to direct effects on ion transport and CFTR 
expression and maturation, Chotirmall et al have recently shown that oestrogens inhibit IL8 
secretion via up-regulation of the secretory leucoprotease inhibitor (SLPI) in an immortalised 
CF cell line.[16] This pathway may directly affect the host response during high oestrogen 
phases of the menstrual cycle. Sex hormones have also been implicated in regulating immune 
and inflammatory responses in various pre-clinical and clinical models.[17] 
 Combined, these results imply that sex hormones may have an effect on CF lung disease. 
Only one short-term study of 12 women assessed lung function in relation to sex hormone 
levels showing that lung function (as measured by forced expiratory volume in 1 second 
(FEV1)) changed in relation to the menstrual cycle. FEV1 was significantly higher during the 
luteal phase (high levels of oestrogen and progesterone) compared to ovulation (high 
oestrogen and low progesterone) and menstruation (low oestrogen and progesterone) .[18]  
 
As the median age of survival increases, more women with CF reach child bearing age and 
use oral contraceptives (OC). [19,20] The use of OC by women with CF provides a clinical 
model in which to test the hypothesis that exogenous oestrogen and/or progesterone  may 
have a significant clinical effect on the course of the disease. Here, we performed a 
retrospective inter- and intra-patient comparison study to assess if OC use affects disease 
severity in CF as measured by annual change in pulmonary function (%FEV1), Body Mass 
Index and the need for intravenous antibiotics.   
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METHODS AND MATERIALS 
Database 
We used information collected at annual review, during a period of clinical stability, for 
patients under the care of the Adult Cystic Fibrosis Unit of Royal Brompton Hospital, 
London.  Information on the use of OC was available for the years 1981-2010 and recorded 
in each year as “Yes”, or “No” or as “Unknown” if the information was missing. Women 
were excluded from analysis if they had ‘Unknown’ OC use for all years of follow-up 
available in the database. We also extracted annual information on percent predicted FEV1 
(%FEV1),  Body Mass Index (BMI) and intravenous (IV) antibiotic use over the previous 
year (total days of treatment).  Data  was taken from the Royal Brompton and Harefield Trust 
CF database . Ethics Committee approval has been granted and all patients on the database 
have signed consent for anonymous data to be used for research purposes. 
 
Inter-patient cohort comparison 
We identified all women who had used OC for a minimum of four out of five years during a 
continuous five year period.  Women in this ‘exposed’ cohort were matched by age to a 
woman who, during the same five year period, had never used OC (‘not exposed’). 
Information on %FEV1, BMI and IV antibiotic use was extracted for each year of the relevant 
five year period; annual changes in %FEV1 and BMI were estimated using linear regression. 
Days of IV antibiotic use during each period were summed. To confirm that the 2 cohorts 
were similar at the start of analysis we compared %FEV1, BMI and days on IV antibiotics at 
the start of analysis.  
 
P a g e  | 6 
 
6 | P a g e  
 
Intra-patient comparison 
In addition to the inter-patient comparison we also decided a priori to perform an intra-patient 
comparison. We identified women (n=27) who used OC for three consecutive years 
(“exposed” period) followed by three years of non-use (“not exposed” period); and, 
conversely and separately, women who did not take OC for three consecutive years followed 
by three years of continuous use (n=23).  As above, annual changes in %FEV1 and BMI were 
estimated for each “exposed” and “not exposed” period using linear regression and days of 
IV antibiotic use during each period were summed. Data obtained for the “exposed” and “not 
exposed” period were then compared for each woman.  
 
Statistical analysis  
Statistical analysis was performed using the GraphPad PRISM 4.0 software package (San 
Diego, CA). After assessment of normal distribution, parametric data were analysed using an 
unpaired or paired Student t-test, as appropriate.  Non-parametric data were analysed using 
the Mann-Whitney U test and the Wilcoxon-matched pairs test for unpaired data and paired 
data, respectively. The null hypothesis was rejected at p<0.05.  
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RESULTS 
Patient demographics 
In the period from 1981 to 2010, 42% of women on the database (n=286 women between 16-
49 years old) reported use of OC on at least one annual review. Forty three percent (n=290) 
had never used OC and 15% (n=104) had never responded either ‘Yes’ or ‘No’ and were 
therefore excluded from subsequent consideration (see Table 1 for basic patient 
demographics). Years of OC use ranged from 1 (n=101) to 21 years (n=1), but approximately 
33% (n=93) of women had continuously used OC for 4 to 5 years. This frequency dropped to 
~10% (n=31) for women who had continuously used OC for 6 to 7 years. 
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Table 1: Comparison of age, %FEV1, BMI and days on intravenous antibiotics in 
women with CF using oral contraceptives (“exposed” cohort) and in women with CF 
not using OC (“not exposed” cohort) in the first year of analysis 
Parameter  All females  'Exposed' cohort  
'Not exposed' 
cohort  p-value  
Age in years 
23 23 22 
0.995 (16-45) (16-45) (17-44) 
n  112 56 56 
% FEV1 
52.5 56.2 48.4 
0.73 (12.8-119.6)   (20.4-111.1)  (12.8-119.6)  
n  110 55 55 
BMI 
20.1 20.1 20.1 
0.98 (15.0-28.2)   (15.2-28.2)  (15.0-26.1)  
n  110 55 55 
Days on IV 
Antibiotics 
0 0 7 
0.38 (0-126)  (0-70)  (0-126)  
n  108 54 54 
 
%FEV1 = percentage predicted forced expiratory volume in one second, BMI=body mass 
index. IV=intravenous. Median and range are shown. p values relate to comparisons between 
women exposed and not exposed to OC. There were no significant differences. 
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Inter-patient cohort comparison 
Women were assigned to the “exposed” and “not exposed” cohorts as outlined in Figure 1. 
Ninety three were identified for the “exposed” cohort; the database was then screened for 
“matching” women who had never taken OC (“not exposed” cohort) and 57 pairs were 
identified. However, incomplete data for the study period led to the subsequent exclusion of a 
further two (for %FEV1 and BMI analysis) or three (analysis of IV antibiotic use) matched 
pairs. 
Comparison of subjects in the exposed and non-exposed groups at the start of the analysis 
period (Year 1) showed that they were of similar age. Women who had not taken OC had a 
lower median %FEV1 and more days on IV antibiotics, but this did not reach significance 
(Table 1).  
There were  no differences between the two cohorts in annual change in %FEV1 during the 
period of analysis (‘exposed’ = -1.87 Δ%FEV1 (range: -11.5 to 10.4); ‘not exposed’ = -1.03 
Δ%FEV1 (range: -11.9 to 17.9), p=0.115, n=55/group) (Figure 2A), in annual change in BMI  
(‘exposed’ = 0.05 ΔΒΜΙ (range: -1.05 to 1.57); ‘not exposed’=  -0.07 ΔΒΜΙ (range: -1.54 to 
3.25), p=0.891, n=55/group) (Figure 2B) or in total days of IV antibiotics  (‘exposed’ = 49 
days (range: 0 – 308); ‘not exposed’= 42 days (range: 0 – 378), p=0.685, n=54/group) 
(Figure 2C ).  
Subgroup analysis using < or  ≥ the median age of 23 years was also performed. Within each 
age group there was no difference in annual change in %FEV1 (<23: p=0.062, ≥23: n=27, 
p=0.762), BMI (<23: p=0.869, ≥23: p=0.876), or total days of IV antibiotics (<23:  p=0.468,  
≥23: p=0.860) (Figure 3A-C and Table 2). When all subject younger than 23 at the start of 
analysis were compared to all subjects equal to or older than 23 at the start of analysis there 
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was a significant difference between the groups for all three parameters during the five year 
period (annual change in %FEV1: p <0.005, annual change in BMI: p <0.05, total days of IV 
antibiotics:  p <0.05) (Figure 3A-C and Table 2) indicating that younger women with CF 
have a steeper rate of decline in FEV1 and BMI, and a greater IV antibiotic usage than older 
women. 
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Table 2: Inter-patient comparison of annual change in %FEV1 and BMI, and total days 
on intravenous antibiotics over a 5 year period in women with CF younger than 23 
years and 23 years or older using oral contraceptives (“exposed” cohort) and not using 
OC (“not exposed” cohort)  
Age in 
years Group 
Annual median 
(range) change in 
%FEV1 
Annual median 
(range) change 
in BMI: units 
Median (range) 
intravenous 
antibiotic use over 
5 years (days) 
    n   n   n   
<23 all 54 -2.25  
(-11.81-13.1) 
54 -0.08  
(-1.53-1.13) 
51 56  
(0-364) 
≥23 all 56 -0.74  
(-8.63-10.4) 
56 -0.12  
(-1.52-3.25) 
57 28  
(0-378) 
  p   <0.005   <0.05   <0.05 
<23 ‘exposed’ 26 -2.86  
(-11.51-8.97) 
26 -0.025  
(-1.05-0.719)
25 56  
(0-224) 
<23 ‘unexposed’ 27 -1.52  
(-11.82-13.11)
28 -0.16  
(-1.54-1.13) 
26 63  
(0-364) 
  p   0.062   0.869   0.468 
≥23 ‘exposed’ 29 -0.74  
(-8.63-10.36) 
29 0.11  
(-0.93-1.57) 
29 28  
(0-308) 
≥23 ‘unexposed’ 27 -0.74  
(-7.98-3.14) 
27 0.17  
(-1.52-3.25) 
28 28  
(0-378) 
  p   0.762   0.876   0.86 
 
∆%FEV1 = annual change in percentage predicted forced expiratory volume in one second, 
∆BMI=annual change in body mass index. IV=intravenous. Median and range are shown. p 
values relate to comparisons between women exposed and not exposed to OC 
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Intra-patient cohort comparison  
We next assessed annual change in %FEV1 and BMI and total days on IV antibiotics over a 
period of OC use (“exposed” period) and a period of no OC use (“not exposed” period) in the 
same woman (see Figure 1 for selection criteria). There were no differences in any of the 
parameters when comparing periods of OC use to periods of no OC use regardless of order 
(Table 3).  
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Table 3: Intra-subject comparison of disease severity during adjacent 3 year periods of 
oral contraceptive (OC) use (“exposed” period) and no OC use (“not exposed” period). 
Women with 3 years of OC use (“exposed” period) followed by 3 years of no OC (“not 
exposed” period) or 3 years of no OC use (“not exposed” period) followed by 3 years of OC 
use (“exposed” period) were included in the analysis. Annual change (Δ) in percentage 
predicted forced expiratory volume in 1 second (%FEV1), annual change in body mass index 
(BMI) and total number of days of IV antibiotic were compared for each 3 year study period. 
Median and range are shown. p values indicate comparison between values for age of 
women. There were no significant differences between the groups. 
Parameter  Exposed Period Not Exposed Period p-value 
Δ% FEV1 -0.40 -2.00 
0.265   (-22.4 to 7.55)   (-16.70 to 4.85)  
n  27 27 
ΔBMI -0.02 -0.02 
0.316   (-0.64 to 1.64)  (-1.4 to 1.54) 
n  27 27 
Days on IV 
Antibiotics 28 28 
0.567   (0 to 84)   (0 to 168)  
n  25 25 
Parameter  Not Exposed Period Exposed Period p-value 
Δ% FEV1 -1.83 -2.35 
0.426   (-15.50 to 6.60)   (-9.30 to 6.65)  
n  23 23 
ΔBMI -0.01 -0.27 
0.618   (-1.62 to 1.30)  (-1.87 to 1.38) 
n  24 24 
Days on IV 
Antibiotics 42 56 0.725 
  (0 to 140)   (0 to 238)  
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n  23 23 
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DISCUSSION 
The literature assessing the effects of sex hormones on ion transport in airway epithelial cells 
is conflicting and studies proposing potential beneficial and detrimental effects of oestrogen 
on ion transport in CF have been published. Here, we conducted a retrospective study aimed 
at assessing the effect of oral contraceptive (OC) use in woman with CF.  Our data suggest 
that OC use does not affect CF disease severity. 
As the median age of survival increases more women with CF reach child bearing age and 
use oral contraceptives. [19,20] In our centre approximately 43% of woman with CF reported 
OC use at least once when questioned during annual follow-up, a percentage similar to 
frequencies reported by Conway et al.[21] However, the effects of OC on disease severity 
have not been extensively studied. We are aware of only one comparatively small and short 
study which assessed the effect of OC on lung function. Fitzpatrick et al studied 12 women 
using OC and reported that lung function did not decline over a six month period.[19] Our 
study over 5 years of follow up which may provide a better opportunity to observe either 
detrimental or beneficial effects of OC on CF disease. We observed an approximately 1-2% 
drop in FEV1% predicted per year in our cohorts which is consistent with most recent 
published data,[22] although reported rates of decline vary (see below). Importantly the 
decline in lung function in women using and not using OC was similar. In addition, subgroup 
analysis in younger (less than 23 years) and older (23 years and older) women did not 
indicate an effect of OC on disease severity.  
 
Consistent with data collated from other  registries [22] we have shown here that lung 
function in women with CF below the age of 23 declines more rapidly than in older women. 
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The reasons for the steeper decline in FEV1 from early adolescence to early adulthood are 
poorly understood, but we show here that the younger population also has a lower BMI and 
an increased need for IV antibiotics. Importantly, we have shown that OC use does not alter 
the decline in lung function in this younger cohort.  
The reported rate of decline in lung function (% FEV1) varies from study to study ([23] and 
references within) and also appears to be birth cohort dependent.[23] Reported values range 
from 0.6 to 4% decline in FEV1 per year. In addition, several studies have shown that anti-
inflammatory drugs such as prednisone and ibuprofen improve, or slow, the decline of lung 
function over a 2 to 4 years study period.[24-26] It is, therefore, reasonable to expect a 
significant positive or negative effect of OC use to become apparent over a 3 to 5 year study 
period. Milder detrimental or protective effects of OC would probably become more obvious 
the longer the period of continuous use of OC. This, however, needs to be balanced against 
the inverse relationship between length of OC use and available patient numbers. For 
example only ~10% (n=31) of CF women in our database had taken OC for a continuous 
period of 6 or 7 years. The inter-patient cohort comparison had sufficient statistical power  to 
detect an approximately 10% difference in the absolute value of %FEV1 in women “exposed” 
and “not exposed” to OC. Smaller effects of OC on lung function may have been missed, but 
are unlikely to have been  ofclinical significance. For the inter-patient analysis we matched 
woman for year of birth and age to minimise birth cohort and age-related disease severity 
effects. Further we assessed the effects of OC use on three key markers of CF disease 
severity; lung function as measured by %FEV1, body mass index (BMI) and intravenous 
antibiotic use. To assess if age at time of OC use is an important variable, we also performed 
a subgroup analysis in younger (less than 23 years) and older (23 years or older), but again 
OC did not appear to have an effect. 
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In addition to inter-patient analysis we also performed an intra-patient analysis, by comparing 
periods of OC use to, subsequent periods of no OC use in the same patient and vice versa. 
Intra-patient analysis is less likely to be affected by confounding factors such as genetics, 
environment or medication. As noted above we had to balance the need for prolonged use of 
OC against available patient numbers and, therefore, restricted the intra-patient analysis to 
three year periods of OC/no OC use. 
The lack of effect in our study is in contrast to previous studies in asthma where oestrogens 
have been shown to affect disease severity in female asthmatics. During low oestrogen phases 
of the menstrual cycle hospitalization and exacerbation rates appear to be increased and lung 
function reduced.[27-29] In addition, OC use has reduced exacerbation rates and improved 
lung function in some asthmatic women.[17] 
Similar to other retrospective studies, our study has a number of limitations. (1) We have no 
information about the type of OC used. OC have been available in Britain since 1960 with the 
original pill containing oestrogen and progesterone.[30] However, more recently only 
progesterone containing “mini pills” have become widely available, although combination 
pills are still in use. In vitro studies have shown that progesterone can also impair chloride 
ion transport [31] or increase CFTR expression.[14] (2) Women with CF routinely require 
antibiotics and it has been well described that antibiotics can impair the effectiveness of OC 
by reducing circulating estradiol levels.[32] We do not have pharmacokinetic data assessing 
hormone concentrations in our patient population and, therefore, cannot completely exclude 
that circulating estrogen and/or progesterone levels may have been affected by simultaneous 
antibiotic intake and may have been too low to affect ion transport properties. However, to 
the best of our knowledge, the rate of unplanned pregnancies in women with CF is not higher 
than in the general population, which implies that circulating hormone levels are not 
significantly reduced by the antibiotics. (3) We have no information, as to why women were 
P a g e  | 18 
 
18 | P a g e  
 
using OC. Avoidance of pregnancy is the most likely explanation, but prevention of irregular 
menstruation may also be a reason. Women may be using OC because they are very well and 
want to avoid pregnancy or they make take OC because their health has declined and would, 
therefore, not be able to cope with pregnancy. It is conceivable that these scenarios may have 
led to significant differences in disease severity between the two cohorts. However, we 
assessed stratification of the cohorts at the start of the study period and showed that there 
were no differences in disease severity as measured by %FEV1, BMI and use of IV 
antibiotics. (4) We carefully matched cohort subjects for year of birth and time-period and era 
of OC use or non-use, but did not match for other variables which may influence disease such 
as age of first Pseudomonas aeruginosa isolate and treatments during the study period, which 
would have further reduced numbers. (5) Missing data or the lack of appropriate control 
subjects can be a problem in retrospective studies; we had to exclude 15% of women because 
we did not have any information related to OC use or because appropriate controls could not 
be identified. However, we think it improbable that any missing or erroneous information on 
the database will be systematically related to our study hypothesis and thus is unlikely to 
have produced any bias in our findings. (6) The study is based on data collected in a single 
centre and reproducibility of the results should ideally be assessed nationwide. However, 
current UK and US registry data do not record this.  We are currently assessing if questions 
related to types of OC used and reasons for OC use could be usefully added to the annual 
review questionnaire, to allow us to collect longitudinal data, which may help to reinforce the 
conclusions drawn in this study. 
In summary, OC use did not affect %FEV1, BMI or the need for intravenous antibiotics. 
These findings, therefore, suggest that the use of OC does not affect CF disease severity. 
P a g e  | 19 
 
19 | P a g e  
 
 
ACKNOWLEDGMENTS 
We thank Marilou Balkin for help with the Dendrite database and Lucinda Hellings for help 
with preparing the manuscript. The work was in part funded by the Cystic Fibrosis Trust and 
the Dr Benjamin Angel Senior Fellowship (UG).  The project was supported by the NIHR 
Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS 
Foundation Trust and Imperial College London. 
P a g e  | 20 
 
20 | P a g e  
 
 
REFERENCES 
[1]  Kreindler JL. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. 
Pharmacol Ther 2010; 125(2): 219-29. 
[2]  Dorfman R, Zielenski J. Genotype-Phenotype Correlations in Cystic Fibrosis. In: Bush 
A, Alton EWFW, Davies JC, Griesenbach U, Jaffe A, editors. Cystic Fibrosis in the 
21st Century.London: Karger; 2009. pp. 61-8. 
[3]  Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in 
the UK: 1947-2003. Eur Respir J 2007; 29(3): 522-6. 
[4]  Hodson ME, Simmonds NJ, Warwick WJ, Tullis E, Castellani C, Assael B, Dodge JA, 
Corey M. An international/multicentre report on patients with cystic fibrosis (CF) over 
the age of 40 years. J Cyst Fibros 2008; 7(6): 537-42. 
[5]  Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic 
fibrosis mortality. Am J Epidemiol 1997; 145(9): 794-803. 
[6]  Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary 
function decline in patients with cystic fibrosis. J Pediatr 1997; 131(6): 809-14. 
[7]  Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas 
aeruginosa infection. J Clin Epidemiol 1995; 48(8): 1041-9. 
P a g e  | 21 
 
21 | P a g e  
 
[8]  Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? Chest 
2005; 128(4): 2824-34. 
[9]  Sweezey NB, Smith D, Corey M, Ellis L, Carpenter S, Tullis DE, Durie P, O'Brodovich 
HM. Amiloride-insensitive nasal potential difference varies with the menstrual cycle in 
cystic fibrosis. Pediatr Pulmonol 2007; 42(6): 519-24. 
[10]  Singh AK, Schultz BD, Katzenellenbogen JA, Price EM, Bridges RJ, Bradbury NA. 
Estrogen inhibition of cystic fibrosis transmembrane conductance regulator-mediated 
chloride secretion. J Pharmacol Exp Ther 2000; 295(1): 195-204. 
[11]  Coakley RD, Sun H, Clunes LA, Rasmussen JE, Stackhouse JR, Okada SF, Fricks I, 
Young SL, Tarran R. 17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway 
surface liquid volume in human cystic fibrosis airway epithelia. J Clin Invest 2008; 
118(12): 4025-35. 
[12]  Nobuzane T, Tashiro S, Kudo Y. Morphologic effects of epithelial ion channels on the 
mouse uterus: differences between raloxifene analog (LY117018) and estradiol 
treatments. Am J Obstet Gynecol 2008; 199(4): 363-6. 
[13]  Rowlands DK, Tsang LL, Cui YG, Chung YW, Chan LN, Liu CQ, James T, Chan HC. 
Upregulation of cystic fibrosis transmembrane conductance regulator expression by 
oestrogen and Bak Foong Pill in mouse uteri. Cell Biol Int 2001; 25(10): 1033-5. 
[14]  Laube M, Kuppers E, Thome UH. Modulation of sodium transport in alveolar epithelial 
cells by estradiol and progesterone. Pediatr Res 2011; 69(3): 200-5. 
P a g e  | 22 
 
22 | P a g e  
 
[15]  Fanelli T, Cardone RA, Favia M, Guerra L, Zaccolo M, Monterisi S, De ST, Riccardi 
SM, Reshkin SJ, Casavola V. Beta-oestradiol rescues DeltaF508CFTR functional 
expression in human cystic fibrosis airway CFBE41o- cells through the up-regulation of 
NHERF1. Biol Cell 2008; 100(7): 399-412. 
[16]  Chotirmall SH, Greene CM, Oglesby IK, Thomas W, O'Neill SJ, Harvey BJ, 
McElvaney NG. 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating 
secretory leucoprotease inhibitor. Am J Respir Crit Care Med 2010; 182(1): 62-72. 
[17]  Haggerty CL, Ness RB, Kelsey S, Waterer GW. The impact of estrogen and 
progesterone on asthma. Ann Allergy Asthma Immunol 2003; 90(3): 284-91. 
[18]  Johannesson M, Ludviksdottir D, Janson C. Lung function changes in relation to 
menstrual cycle in females with cystic fibrosis. Respir Med 2000; 94(11): 1043-6. 
[19]  Fitzpatrick SB, Stokes DC, Rosenstein BJ, Terry P, Hubbard VS. Use of oral 
contraceptives in women with cystic fibrosis. Chest 1984; 86(6): 863-7. 
[20]  Plant BJ, Goss CH, Tonelli MR, McDonald G, Black RA, Aitken ML. Contraceptive 
practices in women with cystic fibrosis. J Cyst Fibros 2008; 7(5): 412-4. 
[21]  Conway SP, Morton AM, Oldroyd B, Truscott JG, White H, Smith AH, Haigh I. 
Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence 
and associated factors. Thorax 2000; 55(9): 798-804. 
P a g e  | 23 
 
23 | P a g e  
 
[22]  Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, Wagener JS. Year-
to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010; 
9(4): 250-6. 
[23]  Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with 
cystic fibrosis. Thorax 2006; 61(2): 155-7. 
[24]  Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of 
alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis 
Foundation Prednisone Trial Group. J Pediatr 1995; 126(4): 515-23. 
[25]  Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in 
patients with cystic fibrosis. N Engl J Med 1995; 332(13): 848-54. 
[26]  Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic 
fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151(3): 249-54. 
[27]  Eliasson O, Scherzer HH. Recurrent respiratory failure in premenstrual asthma. Conn 
Med 1984; 48(12): 777-8. 
[28]  Eliasson O, Scherzer HH, DeGraff AC, Jr. Morbidity in asthma in relation to the 
menstrual cycle. J Allergy Clin Immunol 1986; 77(1 Pt 1): 87-94. 
[29]  Gibbs CJ, Coutts II, Lock R, Finnegan OC, White RJ. Premenstrual exacerbation of 
asthma. Thorax 1984; 39(11): 833-6. 
P a g e  | 24 
 
24 | P a g e  
 
[30]  Junod SW, Marks L. Women's trials: the approval of the first oral contraceptive pill in 
the United States and Great Britain. J Hist Med Allied Sci 2002; 57(2): 117-60. 
[31]  Sweezey NB, Gauthier C, Gagnon S, Ferretti E, Kopelman H. Progesterone and 
estradiol inhibit CFTR-mediated ion transport by pancreatic epithelial cells. Am J 
Physiol 1996; 271(5 Pt 1): G747-G754. 
[32]  Dickinson BD, Altman RD, Nielsen NH, Sterling ML. Drug interactions between oral 
contraceptives and antibiotics. Obstet Gynecol 2001; 98(5 Pt 1): 853-60. 
 
P a g e  | 25 
 
25 | P a g e  
 
FIGURE LEGENDS:  
Figure 1: Flow chart of patient selection for “exposed” and “not exposed” cohorts for 
inter-patient and intra-patient comparison. OC = oral contraceptive, DoB = date of birth 
 
P a g e  | 26 
 
26 | P a g e  
 
 
Figure 2:  Comparison of disease severity during the five year study period in women 
with CF using oral contraceptives (OC) (“exposed” cohort) and women with CF not 
using OC (“not exposed” cohort).  
 
(A) Annual change in percentage predicted forced expiratory volume in 1 second (%FEV1),  
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(B) annual change in body mass index (BMI)  
P a g e  | 28 
 
28 | P a g e  
 
 
(C) total number of days of IV antibiotic use during the 5 year study period. Each symbol 
represents one individual. Parametric and non-parametric statistical analysis was performed 
as appropriate. Horizontal bars indicate group mean (B) or median (A+C) as appropriate for 
parametric or non-parametric data. 
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Figure 3:  Sub-group analysis comparing disease severity in young and older women 
with CF using oral contraceptives (OC) (“exposed” cohort) and women with CF not 
using OC (“not exposed” cohort). Women were grouped by age (young = < 23 years, older 
= ≥ 23 years) and disease severity in “exposed” and “not-exposed” cohorts was compared.  
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(B) annual change in body mass index (BMI)  
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(C) total number of days of IV antibiotic use during the 5 year study period. Each symbol 
represents one individual. Parametric and non-parametric statistical analysis was performed 
as appropriate.  Horizontal bar indicates group mean (B) or median (A+C) as appropriate for 
parametric or non-parametric data. ** = p<0.005 and * = p<0.05 when comparing younger 
and older subjects. 
